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Decreased striatal adenosine A2A-dopamine D2 receptor
heteromerization in schizophrenia
Marta Valle-León1,2, Luis F. Callado 3,4,5, Ester Aso1,2, María M. Cajiao-Manrique1,2,6, Kristoffer Sahlholm1,2,7,8, Marc López-Cano1,2,
Concepció Soler 2,9, Xavier Altafaj1,2, Masahiko Watanabe10, Sergi Ferré 11, Víctor Fernández-Dueñas1,2,
José M. Menchón4,12,13,14 and Francisco Ciruela 1,2
According to the adenosine hypothesis of schizophrenia, the classically associated hyperdopaminergic state may be secondary to a
loss of function of the adenosinergic system. Such a hypoadenosinergic state might either be due to a reduction of the extracellular
levels of adenosine or alterations in the density of adenosine A2A receptors (A2ARs) or their degree of functional heteromerization
with dopamine D2 receptors (D2R). In the present study, we provide preclinical and clinical evidences for this latter mechanism. Two
animal models for the study of schizophrenia endophenotypes, namely the phencyclidine (PCP) mouse model and the A2AR
knockout mice, were used to establish correlations between behavioural and molecular studies. In addition, a new AlphaLISA-based
method was implemented to detect native A2AR-D2R heteromers in mouse and human brain. First, we observed a reduction of
prepulse inhibition in A2AR knockout mice, similar to that observed in the PCP animal model of sensory gating impairment of
schizophrenia, as well as a significant upregulation of striatal D2R without changes in A2AR expression in PCP-treated animals. In
addition, PCP-treated animals showed a significant reduction of striatal A2AR-D2R heteromers, as demonstrated by the AlphaLISA-
based method. A significant and pronounced reduction of A2AR-D2R heteromers was next demonstrated in postmortem caudate
nucleus from schizophrenic subjects, even though both D2R and A2AR were upregulated. Finally, in PCP-treated animals, sub-
chronic administration of haloperidol or clozapine counteracted the reduction of striatal A2AR-D2R heteromers. The degree of A2AR-
D2R heteromer formation in schizophrenia might constitute a hallmark of the illness, which indeed should be further studied to
establish possible correlations with chronic antipsychotic treatments.
Neuropsychopharmacology (2021) 46:665–672; https://doi.org/10.1038/s41386-020-00872-9
INTRODUCTION
Schizophrenia is a complex psychiatric disorder with a hetero-
geneous genetic and neurobiological background, which influ-
ence early brain development [1]. The most accepted mechanistic
hypothesis of schizophrenia is based on a simultaneous dereg-
ulation of glutamatergic and dopaminergic systems [1, 2]. In 1967,
Van Rossum [3] proposed a dopaminergic basis of schizophrenia,
an increase in dopaminergic neurotransmission. Indeed, most
individuals with schizophrenia are behaviourally supersensitive to
drugs inducing activation of dopamine receptors [4] and the
positive symptoms are thought to be associated with hyperactiva-
tion of the dopaminergic system. Early work analyzing post-
mortem brains from patients with schizophrenia revealed a higher
striatal density of dopamine D2 receptors (D2Rs) [5]. Recent
neuroimaging studies indicate that striatal D2R are augmented by
about 5.8 ± 2.7% in schizophrenic subjects [6] and it has been
postulated that the D2R population with higher affinity for
dopamine are preferentially involved [7], although with some
considerations [8]. Thus, a meta-analysis of imaging studies
supported the elevation in the D2R availability but gave more
significance to a presynaptic component of dopamine release [8].
In agreement with the involvement of dopamine and D2R in
schizophrenia, classical antipsychotics such as haloperidol [9] are
D2R antagonists or weak partial agonists [10]. However, although
efficacious against positive symptoms, haloperidol and related
compounds induce severe side effects, including motor impair-
ments [11].
The purinergic system may also be involved in the biology of
psychiatric disorders, including schizophrenia [12]. Indeed, the
adenosine hypothesis of schizophrenia [13, 14] posits that
dysregulation of both glutamatergic and dopaminergic signalling
are secondary to a hypoadenosinergic state. The adenosinergic
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control of the striatal dopaminergic system largely depends on the
existence of complexes (i.e., heteromers) formed by adenosine
and dopamine receptors, more specifically heteromers of adeno-
sine A2A receptors (A2Rs) and D2R [15]. Accordingly, a hypoade-
nosinergic state, with a decline in extracellular adenosine
concentration or a relative downregulation of A2AR vs. D2R, would
reduce the well-established tonic A2AR-mediated inhibition of D2R
function in the A2AR–D2R heteromer [15]. It has therefore been
postulated that increasing A2AR-mediated allosteric inhibition of
D2R within the striatopallidal GABA pathway might represent a
promising strategy for schizophrenia management [15–17]. In line
with this, administration of a selective A2AR agonist effectively
antagonized phencyclidine (PCP)-induced locomotor activity in
rats [18], an animal model of schizophrenic symptomatology [19].
Similarly, the non-selective adenosine receptor antagonist caffeine
has been described to exacerbate psychosis in schizophrenic
patients [20].
The present study aimed at exploring potential alterations of
A2AR and D2R striatal expression and their degree of heteromer-
ization in mice treated sub-chronically with PCP and in
postmortem striatal tissue from schizophrenic subjects, using
our recently developed AlphaLISA-based approach [21]. Further-
more, we evaluated whether sub-chronic treatment with the
typical antipsychotic haloperidol and the atypical antipsychotic
clozapine could modify these alterations in PCP-treated mice.
METHODS AND MATERIALS
Human brain samples
Postmortem human brain samples were obtained at autopsy in
the Basque Institute of Legal Medicine, Bilbao, Spain. The study
was carried out in compliance with the policies of research and
ethical review boards for postmortem brain studies at the
moment of sample collection (Basque Institute of Legal Medicine,
Bilbao). After a retrospective search for antemortem medical
information, ten brain samples of subjects diagnosed with
schizophrenia according to DSM-IV, DSM-IV-R or CIE-10 criteria
were matched to ten control subjects in a paired design. Mean
age, postmortem interval, RNA integrity number, brain pH or
tissue storage time did not differ significantly between controls
and schizophrenic subjects (Supplementary Table S1). Samples
from the caudate nucleus were dissected at autopsy following
standard procedures and were immediately stored at −70 °C until
assay. For every experimental procedure, each subject ascribed to





−/− mice generated on a CD-1 genetic back-
ground [22, 23] and the corresponding littermates weighing
20–25 g were used. The animal protocol (#7085) was approved by
the University of Barcelona Committee on Animal Use and Care.
Animals were housed and tested in compliance with the
guidelines provided by the Guide for the Care and Use of
Laboratory Animals [24] and following the European Union
directives (2010/63/EU). Mice were housed in groups of five in
standard cages with ad libitum access to food and water and
maintained under a 12 h dark/light cycle (starting at 7:30 a.m.),
22 °C temperature and 66% humidity (standard conditions).
Drug administration
PCP (10mg/kg, subcutaneously; Tocris, Bristol, UK), haloperidol
(0.1 mg/kg, intraperitoneally (i.p.); Tocris) and clozapine (10 mg/kg,
i.p.; Tocris) were dissolved in physiological saline (NaCl 0.9%)
and administered for 5 consecutive days. At the end of treatment
(2–3 h after the final drug administration) animals were used for
behavioural assessments and biochemical experiments.
Prepulse inhibition of the acoustic startle response
Mice aged 2–3 months were first handled for 5 days prior to
behavioural tests. All the tests were performed during the light
phase of the circadian cycle (between 8:30 and 14:00 h) by a
researcher blind to drug treatments. At the end of the trial, mice
were briefly returned to their home cage before being used in
biochemical experiments. Prepulse inhibition (PPI) test was
performed using the StartFear System (Panlab, Cornellà de
Llobregat, Spain), as described in detailed elsewhere [25] and in
the Supplementary Information.
Determination of ribonucleosides and monoamines in mouse
striatum
Mice were rapidly killed by cervical dislocation and 400 μm brain
coronal sections were obtained in carbogen (95% O2 and 5% CO2)
bubbled artificial cerebrospinal fluid buffer (127 mM NaCl, 1 mM
KCl, 1.2 mM KH2PO4, 26 mM NaHCO3, 10mM D-glucose, 2.4 mM
CaCl2 and 1.3 mM MgCl2, pH 7.4). Next, the striatum was dissected
from the slice and homogenized in 200 μl of acetonitrile
(Sigma-Aldrich) containing 2% CH3COOH (Sigma-Aldrich) and
dC-d3 (1 ng/µl) at 4 °C in a 1 ml Potter–Elvehjem glass tube using a
homogenizer stirrer HS-30E (Witeg Labortechnik GmbH,
Wertheim, Germany) with 10 strokes at 700–900 rotations per
min. Finally, samples were centrifuged at 13,200 r.p.m. at 4 °C for
20min and the supernatants were stored at −80 °C until analysis.
Quantitative analysis of ribonucleosides (i.e., adenosine, cytidine,
guanosine and uridine) and monoamines (i.e., dopamine and
serotonin) was carried out by liquid chromatography technique
coupled with tandem mass spectrometry and is described in detail
in the Supplementary Information.
Immunohistofluorescence analysis
Mice were anaesthetized and perfused intracardially with 100–200
ml ice-cold 4% paraformaldehyde (PFA) in phosphate-buffered
saline (PBS; 8.07mM Na2HPO4, 1.47mM KH2PO4, 137mM NaCl, 0.27
mM KCl, pH 7.2). Brains were post-fixed in the same solution of PFA
at 4 °C during 12 h. Coronal sections (50 μm) were obtained using a
vibratome (Leica Lasertechnik GmbH, Heidelberg, Germany). Slices
were collected in Walter’s Antifreezing solution (30% glycerol, 30%
ethylene glycol in PBS, pH 7.2) and kept at −20 °C until processing.
For immunohistofluorescence analysis, the slices were washed three
times with PBS, permeabilized with 0.5% Triton X-100 in PBS for 2 h
and rinsed again three times with washing solution (0.05% Triton X-
100 in PBS). The slices were then incubated with washing solution
containing 10% normal donkey serum (NDS; Jackson ImmunoR-
esearch Laboratories, Inc., West Grove, PA, USA) for 2 h at room
temperature. Subsequently, slices were incubated with goat anti-
A2AR (3 µg/ml; Santa Cruz Biotechnology, Inc., Dallas, TX, USA),
rabbit anti-D2R (3 µg/ml; Frontier Institute Co. Ltd, Hokkaido, Japan)
or goat anti-DAT (0.5 µg/ml; Santa Cruz Biotechnology, Inc.) in
washing solution containing 10% NDS for 24 h at 4 °C. Next, slices
were washed with washing solution containing 1% NDS before the
incubation with Cy3-conjugated donkey anti-goat or Cy2-
conjugated donkey anti-rabbit IgG antibody (1 : 200; Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) in washing
solution for 2 h at room temperature. Finally, slices were washed
twice with washing solution containing 10% NDS and then
mounted with Vectashield immunofluorescence medium (Vector
Laboratories, Peterborough, UK) in glass slides. Fluorescence striatal
images were captured using a Leica TCS 4D confocal scanning laser
microscope (Leica Lasertechnik GmbH).
Gel electrophoresis and immunoblotting
Mouse striatum or frozen human caudate were homogenized in
ice-cold 10 mM Tris HCl, pH 7.4, 1 mM EDTA, 300mM KCl buffer
containing a protease inhibitor cocktail (Roche Molecular Systems,
USA) using a Polytron for three periods of 10 s each. The
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homogenate was centrifuged for 10 min at 1000 × g. The resulting
supernatant was centrifuged for 30 min at 12,000 × g. The
membranes were dispersed in 50mM Tris HCl (pH 7.4) and 10
mM MgCl2, washed, and resuspended in the same medium as
described previously [26]. Protein concentration was determined
using the BCA protein assay kit (Thermo Fisher Scientific, Inc.,
Rockford, IL, USA) and 50–80 μg of protein was used for
immunoblotting.
Sodium dodecyl sulfate-polyacrylamide gel electrophoresis was
performed using 10% polyacrylamide gels. Proteins were trans-
ferred to Hybond®-LFP polyvinylidene difluoride (PVDF) membranes
(GE Healthcare, Chicago, IL, USA) using a Trans-Blot® SD Semi-Dry
Transfer Cell (Bio-Rad, Hercules, CA, USA). PVDF membranes were
blocked with 5% (wt/vol) dry non-fat milk in PBS containing 0.05%
Tween-20 (PBS-T) during 45min and immunoblotted using goat
polyclonal anti-A2AR (0.5 μg/ml; Santa Cruz Biotechnology, Inc.),
rabbit polyclonal anti-D2R (1 μg/ml; Frontier Institute Co. Ltd),
guinea pig polyclonal anti-A2AR (1 μg/ml; Frontier Institute Co. Ltd),
goat anti-DAT (0.5 μg/ml; Santa Cruz Biotechnology, Inc.) and rabbit
polyclonal anti-α-actinin (0.5 μg/ml; Santa Cruz Biotechnology, Inc.)
antibodies in blocking solution overnight at 4 °C. PVDF membranes
were washed with PBS-T three times (5min each) before incubation
with either a horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG (1/30,000; Pierce Biotechnology, Rockford, IL, USA), HRP-
conjugated rabbit anti-goat IgG (1/10,000; Pierce Biotechnology) or
HRP-conjugated rabbit anti-guinea pig IgG (1/3,000; Pierce Biotech-
nology) in blocking solution at 20 °C during 2 h. After washing the
PVDF membranes with PBS-T three times (5min each), the
immunoreactive bands were developed using a chemiluminescent
detection kit (Thermo Fisher Scientific, Waltham, MA, USA) and were
detected with an Amersham Imager 600 (GE Healthcare Europe
GmbH, Barcelona, Spain).
AlphaLISA method
Mouse striatal and human caudate membranes were homoge-
nized in AlphaLISA buffer (AlphaLISA HiBlock Buffer, PerkinElmer,
Waltham, MA, EEUU) and protein concentration determined. Thus,
5 μg of protein/well was placed in white 384 well-plates (384 Well
Small Volume™ HiBase Microplates, Greiner Bio-one, Kremsmün-
ster, Austria). Subsequently, membranes were incubated with 5 μl
of 10 nM donor primary antibody plus 5 μl of 10 nM acceptor
primary antibody (rabbit anti-D2R and guinea pig anti-A2AR,
respectively) overnight at 4 °C. As a negative control, samples
were also incubated in the absence of either the acceptor or
donor primary antibody (Supplementary Fig. S1a). In addition,
striatal membranes from A2AR
−/− and D2R
−/− mice were used
negative controls to further validate the new AlphaLISA method
implemented here for the detection of A2AR–D2R heteromers in
native tissue (Supplementary Fig. S1b). All reagents were mixed by
pipetting up and down before incubation. After the overnight
incubation, plates were tempered at 22 °C before acceptor beads
were added. Anti-guinea pig conjugated acceptor beads were
generated by covalent binding of AffiniPure F(ab’)2 Fragment
Donkey Anti-Guinea Pig IgG (H+ L) (Jackson ImmunoResearch
Laboratories, Inc., West Grove, PA, USA) to acceptor beads
(AlphaLisa acceptor beads, 6772001; PerkinElmer) following the
manufacturer’s instructions. Subsequently, acceptor beads were
diluted in AlphaLISA buffer and 5 μL added to each well (final
concentration 40 μg/mL). The reagents were mixed by pipetting.
After 1 h incubation (in darkness at 22 °C), donor beads (anti-rabbit
IgG AlphaLISA Donor beads, AS105D, PerkinElmer) were diluted in
AlphaLISA buffer and 5 μL of diluted beads added to each well
(final concentration 10 μg/mL). The final reaction volume was
30 μL. The reagents were mixed by pipetting. Finally, after 24 h
incubation (in darkness at 4 °C), the microplate was read using a
CLARIOstar plate-reader (BMG Labtech, Durham, NC, USA). The
plate was left in the dark at room temperature and read again at
48 h. A background signal (B) was determined in wells where all
reagents were added without sample. For each membrane brain
sample a negative control (Cn) was determined by incubating in
the absence of acceptor primary antibody (i.e., guinea pig anti-
A2AR antibody). Therefore, for each sample the specific AlphaLISA
signal (i.e., ΔAlphaLISA) was calculated as follows:
ΔAlphaLISA nð Þ ¼ AlphaLISA signalðnÞ  B
 
 CðnÞ  B
 
Statistics
Data are represented as mean ± SEM. The number of samples/
animals (n) in each experimental condition is indicated in the
corresponding figure legend. Data normality was assessed by the
Shapiro–Wilk normality test. Outliers were assessed by the Grubbs’
test; thus, data from any animal found to be an outlier was
excluded. Comparisons among experimental groups were per-
formed by Student’s t-test, one-way analysis of variance (ANOVA)
with Dunnett’s post hoc test or two-way ANOVA with Sidak’s post
hoc test using GraphPad Prism 6.01 (San Diego, CA, USA), as
indicated. Statistical difference was accepted when P < 0.05.
RESULTS
Alterations in sensorimotor gating in PCP-treated animals and in
mice lacking A2AR
The adenosine hypothesis of schizophrenia [13, 14] was recently
bolstered by the observation that A2AR deletion (A2AR
−/−)
prompts behaviours that mimic symptoms of psychosis and
molecular/anatomical alterations in mice, resembling the relevant
phenotype features of the human disorder [23, 27, 28]. We first
validated the A2AR
−/−-based animal model of psychotic symptoms
by comparing it with the well-established PCP animal model of
sensory gating impairment of schizophrenia [19, 29, 30]. A2AR
−/−
and A2AR
+/+ saline- and PCP-treated mice were evaluated with the
PPI test, a classically accepted behavioural assessment of
sensorimotor processing altered in schizophrenic patients and in
PCP-treated rodents [19, 29]. As previously reported [23, 28],
A2AR
−/− mice showed a significant reduction in basal PPI at 70 dB
(P= 0.0156), 75 dB (P= 0.0023) and 80 dB (P= 0.0001) (Fig. 1). PCP
administration to A2AR
+/+ mice also induced a significant PPI
reduction, up to half of basal values, at 70 dB (P= 0.0068), 75 dB
(P= 0.0025) and 80 dB (P= 0.0119) (Fig. 1). These results
demonstrated that sensorimotor processing alterations in
A2AR
−/− mice were comparable to those observed in PCP-
treated wild-type (WT) animals.
Striatal A2AR and D2R expression profiles in A2AR
−/− and PCP-
treated mice
Next, we aimed at determining possible alterations in striatal A2AR
content in the PCP animal model, as well as possible alterations in
striatal D2R densities in PCP-treated and in A2AR
−/− mice groups,
by performing immunoblotting and immunocytochemistry experi-
ments. First, we assessed A2AR and D2R expression by immunoblot
analysis. A2AR and D2R expression was ascertained by the
presence of protein bands of molecular weight ~45 kDa and
~70–80 kDa, respectively (Fig. 2a, d), which were absent in A2AR-
and D2R-knockout mice samples as previously demonstrated [23]
In addition, we assessed the dopamine transporter (DAT), as
alterations in DAT expression have been recently described in
another rodent model of psychosis [31]. Importantly, although
A2AR and DAT expression were not altered in the striatum of PCP-
treated animals, the expression of D2R was significantly increased
(P= 0.0006) (Fig. 2a, b). Immunohistofluorescence analysis of A2AR,
D2R and DAT in coronal slices at the level of the anterior
commissure from PCP-treated mice also revealed higher D2R
immunoreactivity in the striatum (Fig. 2c). Overall, these results
indicate that PCP treatment raised D2R expression in the striatum,
while A2AR and DAT were unaffected.
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Subsequently, we analyzed A2AR, D2R and DAT expression in WT
and A2AR
−/− mice. Similar to what was observed in PCP-treated
mice, immunoblotting analysis revealed that deletion of A2AR
induced a significative increase in D2R (P= 0.0433) but also in DAT
(P= 0.0014) expression in the striatum (Fig. 2d, e). As expected,
A2AR expression was abolished in A2AR
−/− (Fig. 2d, e). In addition,
immunohistofluorescence detection of A2AR, D2R and DAT in WT
mice also revealed increased D2R and DAT immunoreactivity in
the striatum (Fig. 2f). As expected, A2AR immunoreactivity could
not be detected in A2AR
−/− mice (Fig. 2f). Collectively, these results
indicate that the expression of D2R in the striatum of A2AR
−/− mice
is increased, similar to what was observed in the PCP-based
animal model of schizophrenic symptomatology.
Striatal levels of ribonucleosides and monoamines in A2AR
−/− and
PCP-treated mice
To determine a possible presynaptic imbalance, striatal levels of
adenosine and dopamine were determined in A2AR
+/+, A2AR
−/−
and PCP-treated mice. The levels of the ribonucleosides cytidine,
guanosine and uridine, and the monoamine serotonin were also
determined (Supplementary Table S2). Interestingly, although the
levels of dopamine and serotonin were not altered in A2AR
−/− or in
PCP-treated animals, the amounts of adenosine and cytidine were
significantly increased in A2AR
−/− mice (Supplementary Table S2).
Also, the levels of uridine were significantly raised both in A2AR
−/−
and PCP-treated animals (Supplementary Table S2). These results
indicate that purine metabolism is altered in the A2AR
−/− mouse
model, which displays a striatal neurochemical pattern different
from that observed in the PCP model of schizophrenic sympto-
matology. Altogether, the results (i.e., density of striatal A2AR and
D2R, and neurotransmitter levels) obtained from PCP-treated and
A2AR
−/− mouse models do not support a presynaptic
adenosine–dopamine imbalance, but rather support a postsynaptic
A2AR–D2R density imbalance in schizophrenia.
A2AR, D2R and DAT expression profiles in the caudate nucleus from
postmortem schizophrenic subjects
As mentioned in the introductory section, previous postmortem
and imaging studies suggested the presence of an increased
D2R expression in the striatum of schizophrenic subjects [5, 6].
Conversely, the results with DAT and A2AR are inconsistent. A
recent meta-analysis indicates that there is a significantly greater
interindividual variability of striatal DAT availability in patients
with schizophrenia, compared to control subjects. These data
suggest that altered DAT expression may occur only in a group of
patients [32]. Inconsistent results have also been obtained in
relation to striatal A2AR expression in schizophrenia, with reports
of either upregulation or downregulation [33, 34]. Therefore, we
aimed at determining whether the relative expression of D2R, A2AR
and DAT were altered in postmortem caudate from a group of
schizophrenic subjects (Supplementary Table S1). From immuno-
blot analysis of postmortem caudate nucleus membranes
obtained from a cohort of ten healthy controls and ten subjects
diagnosed with paranoid schizophrenia (Supplementary Table S1),
we found that D2R, DAT and A2AR expression was significantly (P <
0.05) increased in the caudate nucleus from subjects with
schizophrenia (Fig. 3a, b).
Decrease in A2AR–D2R heteromerization in the caudate nucleus of
schizophrenic subjects and the striatum of PCP-treated mice
We next interrogated whether the postulated hypoadenosinergic
state in schizophrenia could be dependent on a significant change
in the interactions between A2AR and D2R, i.e., in their well-
established ability to form functional heteromers [15]. To this end,
we used our recently engineered AlphaLISA-based method to
assess A2AR–D2R interactions in human postmortem brain [21]
(Fig. 4a). The AlphaLISA approach revealed a strong and specific
energy transfer between the donor and acceptor beads coupled
to specific receptor antibodies (Supplementary Fig. 1). This energy
transfer confirmed that the intermolecular interaction between
A2AR and D2R, i.e., A2AR–D2R heteromers, can be detected in
postmortem membrane extracts (Fig. 4b), as recently reported
[21]. A significant and pronounced reduction of 59 ± 11% (P=
0.0076) in A2AR–D2R heteromerization was observed in the human
caudate membrane extracts from schizophrenic subjects as
compared to controls (Fig. 4b, right panel). Similarly, when striatal
membrane extracts from PCP-treated animals were assessed, a
comparable significant reduction of 75 ± 7% (P= 0.0001) in
A2AR–D2R heteromerization was detected as compared to controls
(Fig. 4b, left panel). Overall, these results indicate that striatal
A2AR–D2R heteromerization was reduced both in schizophrenic
subjects and in the PCP-based animal model of schizophrenic
symptoms, thus predicting a role for alterations in the formation
of the striatal A2AR–D2R heteromers in the pathophysiology of
schizophrenia.
Counteracting effects of sub-chronic antipsychotic treatment on
PCP-induced reduction of A2AR–D2R heteromerization
In view that schizophrenic patients showed a reduced A2AR–D2R
heteromer formation, we next aimed at determining whether
antipsychotic medications may prevent PCP-mediated A2AR–D2R
heteromer downregulation in mice. Interestingly, previous pre-
clinical experiments evaluating the effects of neuroleptics on
A2AR–D2R interactions found that chronic haloperidol treatment
induced an increase in functional A2AR–D2R interactions. More
specifically, chronic treatment with haloperidol (administered in
drinking water for 30 consecutive days, adjusted to 1.5 mg/kg) in
rats led to an increased potency of A2AR agonists in reducing the
affinity of D2R agonists in striatal membrane preparations and to
an increase in the locomotor-activating effects of the adenosine
receptor antagonist theophylline [35]. However, we could not
evaluate a possible effect of antipsychotics on striatal A2AR–D2R
heteromerization in our cohort sample, since it was limited to ten
subjects with paranoid schizophrenia treated with different
compounds (Supplementary Table S1). Therefore, we aimed at
ascertaining the impact of neuroleptic treatment on A2AR–D2R
heteromer formation in PCP-treated mice. We evaluated the
possible modification of striatal A2AR–D2R heteromerization upon
Fig. 1 Sensorimotor processing in WT, PCP-treated and A2AR
−/−
mice. The prepulse inhibition (PPI) impairment of the acoustic startle
response (ASR) was assessed and expressed as percentage mean ±
SEM (n= 10–15 animals) of inhibition of ASR at the indicated
prepulse acoustic stimulus amplitudes (i.e., 70, 75 and 80 dB). *P <
0.05, **P < 0.01 and ***P < 0.001, one-way ANOVA followed by
Dunnett’s post hoc test compared with WT (A2AR
+/+) group. Two-
way ANOVA (PP × phenotype/PCP) revealed a significant main effect
of phenotype/PCP (F(2,117)= 22.65, P < 0.0001) and a nonsignificant
effect of PP (F(2,117)= 2.616, P= 0.0774) or the interaction between
both factors (F(4,117)= 0.5762, P= 0.6804).
Decreased striatal adenosine A2A-dopamine. . .
M Valle-León et al.
668
Neuropsychopharmacology (2021) 46:665 – 672
administration of haloperidol or clozapine in mice repeatedly
administered with PCP. We could first confirm that sub-chronic
treatment with haloperidol or clozapine did not modify PPI in
control mice. Conversely, they both counteracted PCP-induced
disruption of PPI (Fig. 5a). On the other hand, the AlphaLISA
approach revealed that neither haloperidol nor clozapine mod-
ified A2AR–D2R heteromerization in control mice but prevented
the reduction of A2AR–D2R heteromerization in PCP-treated
animals (Fig. 5b). Finally, when the density of striatal A2AR and
D2R was assessed by immunoblotting, we confirmed that PCP
produced a significant increase in the density of D2R (Fig. 5c, d).
This effect was not modified by haloperidol or clozapine treatment
(Fig. 5c, d). Similarly, in the absence of PCP, neither haloperidol nor
clozapine treatment significantly modified A2AR and D2R densities
(Fig. 5c, d). These results imply that sub-chronic treatment with
haloperidol or clozapine does not lead to an increase in A2AR–D2R
heteromerization in healthy subjects. However, antipsychotics are
able to reverse PCP-induced reduction in striatal A2AR–D2R
heteromerization and, as previously reported [36], PCP-induced
disruption of PPI.
DISCUSSION
Targeting D2R-containing heteromers (i.e., A2AR–D2R) represents a
new strategy for psychosis management [16]. Our results indicate
that the presence of sensitized D2R in schizophrenia may be
concomitant to a reduction in A2AR activity secondary to a
deficiency in A2AR–D2R heteromer formation. Indeed, we observed
a reduction of PPI in A2AR
−/− mice, similar to the PPI deficits in
PCP-treated mice. In addition, these animals showed a significant
upregulation of striatal D2R without concomitant changes in the
expression of A2AR (a relative downregulation of A2AR vs. D2R).
More importantly, we could establish a correlation between
striatal A2AR–D2R heteromer downregulation and PCP-induced
Fig. 2 Expression of A2AR, D2R and DAT in the striatum of PCP-treated and A2AR
−/− mice. a, d Representative immunoblots showing the
expression of A2AR, D2R and DAT in striatal membranes from saline and PCP-treated mice (a) and striatal membranes from WT (A2AR
+/+) and
A2AR
−/− mice (d); striatal membranes were analyzed by SDS-PAGE (50 μg of protein/lane) and immunoblotted using goat anti-A2AR, rabbit
anti-D2R, goat anti-DAT and rabbit anti-α-actinin antibodies (see Methods). b, e) Relative quantification of A2AR, D2R and DAT expression. The
immunoblot protein bands corresponding to A2AR, D2R, DAT and α-actinin from saline and PCP-treated mice (b; n= 6–9) and from WT and
A2AR
−/− mice (e; n= 5–7) were quantified by densitometric scanning; values were normalized to the respective amount of α-actinin in each
lane to correct for protein loading; results are expressed as percentage (mean ± SEM) of the corresponding saline-treated or WT animals; *P <
0.05, **P < 0.01 and ***P < 0.001 two-way ANOVA with Sidak’s post hoc test. c, f Representative images of A2AR, D2R and DAT
immunoreactivities in the dorsal striatum of saline and PCP-treated mice (c) or WT and A2AR
−/− mice (f); scale bar: 350 μm. Cx, cortex; St,
striatum.
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sensory gating impairment in mice. Finally, in schizophrenic
subjects, A2AR–D2R heteromers were also reduced, even though
the expression of both A2AR and D2R was increased.
Apart from the already supported antipsychotic potential for
A2AR agonists [18], drugs promoting A2AR–D2R heteromer forma-
tion might constitute an alternative strategy for the treatment of
schizophrenia. In fact, we could demonstrate that, in the PCP
animal model of schizophrenic symptomatology, sub-chronic
treatment with either the typical antipsychotic, haloperidol, or
the atypical antipsychotic, clozapine, counteracted PCP-induced
PPI disruption and PCP-induced reduction in striatal A2AR–D2R
heteromerization. Conversely, antipsychotics did not change the
degree of A2AR–D2R heteromerization in control animals, without
PCP treatment. A more sustained treatment with antipsychotics
could therefore lead to further increase in striatal A2AR–D2R
heteromerization, as suggested from previous experiments in rats
chronically treated with haloperidol [35]. Upregulation of striatal
A2AR–D2R heteromers could therefore represent a protective
mechanism associated with chronic neuroleptic treatment.
Schizophrenia has a strong heritable component and some
genetic risk factors have been already established. Accordingly,
genetic animal models are important tools to study the
mechanisms underlying this disease. Based on the evidence that
striatal D2R are upregulated in schizophrenic patients [6], an
animal model of schizophrenia based on D2R overexpression in
the striatum (i.e., D2R-OE mice) was created using an artificial
transcription factor system [37]. However, although D2R-OE mice
showed deficits in working memory tasks and behavioural
flexibility, they did not present deficits in PPI [37]. Several gene
knockouts, including those of the metabotropic glutamate mGlu2
and mGlu3 receptors, PSD95 (postsynaptic density protein 95),
GPRK6 (G-protein receptor kinase 6), the Trace Amine-1 receptor,
and RGS9-2 (regulator of G-protein signalling 9-2), have also been
proposed as animal model of psychosis, which may represent
different aspects of the disease [38, 39]. Our results support the
validity of a novel genetic model; A2AR
−/− mice. Thus, similar to
what is observed in the widely used PCP animal model
schizophrenic symptomatology, A2AR
−/− mice display PPI deficits
and increased striatal D2R and DAT densities.
Altogether, the results of the present study provide strong
support to the adenosine hypothesis of schizophrenia [13, 14].
However, rather than pointing to adenosine itself, our data
highlight A2ARs and their fundamental role in controlling striatal
D2R function [15, 16, 40]. Overall, apart from presynaptic
mechanisms [8, 32], the pathophysiology of schizophrenia seems
to involve postsynaptic mechanisms which, rather than be related
to D2R upregulation, it involves the loss of the control of D2R by
A2AR in the striatum. Changes in the density of striatal A2AR-D2R
heteromers should then be expected to contribute to the changes
observed in positron emission tomography (PET) imaging studies
that use D2R ligands in patients with schizophrenia. Those
changes would then depend on the complex allosteric
Fig. 3 Expression of A2AR, D2R and DAT in schizophrenic subjects.
a Representative immunoblot showing the expression of A2AR, D2R
and DAT in postmortem caudate membranes from healthy control
(HC) and schizophrenic (SCZ) subjects; membranes from human
postmortem caudate were analyzed by SDS-PAGE (50 μg of protein/
lane) and immunoblotted using goat anti-A2AR, rabbit anti-D2R, goat
anti-DAT and rabbit anti-α-actinin antibodies (see ‘Methods’).
b Relative quantification of A2AR, D2R and DAT expression; the
immunoblot protein bands corresponding to A2AR, D2R, DAT and α-
actinin from healthy control (n= 10) and schizophrenic (n= 10)
individuals were quantified by densitometric scanning; values were
normalized to the respective amount of α-actinin in each lane to
correct for protein loading. Results are expressed as percentage
(mean ± SEM) of the control. *P < 0.05, **P < 0.01, two-way ANOVA
with Sidak’s post hoc test.
Fig. 4 A2AR–D2R heteromer assessment in mouse striatum and human caudate using an AlphaLISA approach. a Illustration of the specific
AlphaLISA protein–protein interaction assay designed for A2AR–D2R heteromer identification and quantification in native tissue; anti-guinea
pig-coated acceptor beads (red sphere) were generated to capture a guinea pig anti-A2AR antibodies bound to the receptors within the
membrane extract; anti-rabbit coated donor beads (blue sphere) capture the immune complexes between the rabbit anti-D2R antibodies and
the receptors within the membrane extract; A2AR–D2R heteromerization brings donor beads into close proximity (<200 nm) to the acceptor
beads. The excitation of the donor beads at 680 nm generates singlet oxygen (1O2) molecules triggering a chemical reaction within the
acceptor beads, which results in a sharp peak of fluorescent emission at 615 nm (figure designed using image templates from Servier Medical
Art https://smart.servier.com/image-set-download/). b The A2AR–D2R interaction capacity in membranes from saline- (n= 10) and PCP- (n=
10) treated mouse striatum (left panel) or from postmortem control (n= 10) and schizophrenic (n= 10; SCZ) caudate (right panel) was
determined by AlphaLISA method (see ‘Methods’); the specific AlphaLISA signal (i.e., ΔAlphaLISA) was calculated as described in the ‘Methods’
section and expressed as percentage (mean ± SEM) of either the saline-treated mice or control subjects. **P < 0.01 and ***P < 0.001, Student’s
t-test.
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interactions between A2AR and D2R agonists and antagonists that
occur in the A2AR–D2R heteromer, where any orthosteric A2AR
ligand, agonist or antagonist, exerts a negative allosteric modula-
tion on the affinity of any orthosteric D2R ligand, agonist or
antagonist [41]. Those allosteric interactions provided a plausible
mechanism for the reported increase of [11C]raclopride binding in
humans induced by caffeine [42], due to a its ability to antagonize
the effect of endogenous adenosine on the binding of the
exogenous D2R antagonist [41]. It can thus be predicted that a
decrease in A2AR–D2R heteromerization should lead to a reduced
effect of endogenous adenosine on exogenous antagonist
binding, which might be mainly responsible for the increased
striatal D2R antagonist binding of schizophrenic patients.
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heteromerization in striatal membranes from the same animals shown in a determined by AlphaLISA method (see ‘Methods’); the specific
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immunoblot protein bands corresponding to A2AR, D2R, DAT and α-actinin from the same animals shown in a were quantified by
densitometric scanning; values were normalized by the respective amount α-actinin in each lane to correct for protein loading. Results are
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